$MRNA
Moderna, Inc.

2022 Q3 Form 10-Q Financial Statement

#000168285222000042 Filed on August 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $3.364B $4.749B $6.066B
YoY Change -32.3% 9.07% 213.16%
Cost Of Revenue $1.100B $1.381B $1.017B
YoY Change 52.35% 84.13% 426.94%
Gross Profit $2.264B $3.368B $5.049B
YoY Change -46.69% -6.55% 189.51%
Gross Profit Margin 67.3% 70.92% 83.23%
Selling, General & Admin $278.0M $211.0M $268.0M
YoY Change 65.48% 74.38% 248.05%
% of Gross Profit 12.28% 6.26% 5.31%
Research & Development $820.0M $710.0M $554.0M
YoY Change 57.39% 68.65% 38.15%
% of Gross Profit 36.22% 21.08% 10.97%
Depreciation & Amortization $113.0M $76.00M $79.00M
YoY Change 61.43% 10.14% 426.67%
% of Gross Profit 4.99% 2.26% 1.56%
Operating Expenses $820.0M $710.0M $554.0M
YoY Change 57.39% 68.65% 38.15%
Operating Profit $1.166B $2.447B $4.227B
YoY Change -67.23% -20.08% 233.89%
Interest Expense $46.00M $27.00M $3.000M
YoY Change 200.0%
% of Operating Profit 3.95% 1.1% 0.07%
Other Income/Expense, Net -$7.000M -$13.00M -$13.00M
YoY Change -30.0% 550.0% 30.0%
Pretax Income $1.217B $2.474B $4.229B
YoY Change -65.74% -19.23% 235.63%
Income Tax $174.0M $277.0M $572.0M
% Of Pretax Income 14.3% 11.2% 13.53%
Net Earnings $1.043B $2.197B $3.657B
YoY Change -68.71% -20.97% 199.51%
Net Earnings / Revenue 31.0% 46.26% 60.29%
Basic Earnings Per Share $2.67 $5.55 $9.09
Diluted Earnings Per Share $2.53 $5.24 $8.58
COMMON SHARES
Basic Shares Outstanding 391.2M shares 396.0M shares 402.0M shares
Diluted Shares Outstanding 412.0M shares 419.0M shares 426.0M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.348B $7.897B $10.12B
YoY Change -6.27% -1.16% 30.77%
Cash & Equivalents $3.027B $2.873B $5.048B
Short-Term Investments $5.321B $5.024B $5.067B
Other Short-Term Assets $85.00M $76.00M $36.00M
YoY Change 97.67% 100.0% -85.37%
Inventory $2.077B $1.921B $1.942B
Prepaid Expenses
Receivables $2.695B $2.691B $3.173B
Other Receivables $126.0M $153.0M $191.0M
Total Short-Term Assets $14.30B $13.56B $16.35B
YoY Change 6.5% 23.65% 39.71%
LONG-TERM ASSETS
Property, Plant & Equipment $2.132B $1.446B $1.473B
YoY Change 122.08% 61.02% 219.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $8.655B $10.16B $9.171B
YoY Change 34.35% 141.55% 1859.62%
Other Assets $38.00M $75.00M $82.00M
YoY Change 850.0% 3650.0% 8100.0%
Total Long-Term Assets $11.76B $12.48B $11.26B
YoY Change 56.83% 140.74% 1036.13%
TOTAL ASSETS
Total Short-Term Assets $14.30B $13.56B $16.35B
Total Long-Term Assets $11.76B $12.48B $11.26B
Total Assets $26.06B $26.04B $27.61B
YoY Change 24.53% 61.23% 117.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $330.0M $181.0M $199.0M
YoY Change 279.31% 135.06% 2387.5%
Accrued Expenses $1.856B $1.780B $1.608B
YoY Change 72.49% 109.91% 113.55%
Deferred Revenue $4.002B $4.093B $5.599B
YoY Change -49.83% -43.95% -25.65%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $224.0M $121.0M $160.0M
YoY Change 2.75% -23.9% 255.56%
Total Short-Term Liabilities $6.807B $6.812B $9.238B
YoY Change -31.64% -22.94% 9.44%
LONG-TERM LIABILITIES
Long-Term Debt $922.0M $641.0M $646.0M
YoY Change 287.39% 95.43% 368.12%
Other Long-Term Liabilities $81.00M $113.0M $91.00M
YoY Change 8000.0% 11200.0% 4450.0%
Total Long-Term Liabilities $81.00M $113.0M $91.00M
YoY Change 8000.0% 11200.0% 4450.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.807B $6.812B $9.238B
Total Long-Term Liabilities $81.00M $113.0M $91.00M
Total Liabilities $8.064B $8.058B $10.53B
YoY Change -25.33% -14.72% 18.95%
SHAREHOLDERS EQUITY
Retained Earnings $16.86B $15.81B $13.62B
YoY Change 231.14% 799.94% -1430.89%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.99B $17.99B $17.08B
YoY Change
Total Liabilities & Shareholders Equity $26.06B $26.04B $27.61B
YoY Change 24.53% 61.23% 117.5%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $1.043B $2.197B $3.657B
YoY Change -68.71% -20.97% 199.51%
Depreciation, Depletion And Amortization $113.0M $76.00M $79.00M
YoY Change 61.43% 10.14% 426.67%
Cash From Operating Activities $252.0M $304.0M $2.763B
YoY Change -92.31% -92.52% -7.0%
INVESTING ACTIVITIES
Capital Expenditures -$89.00M -$87.00M $132.0M
YoY Change -10.1% 190.0% 277.14%
Acquisitions $0.00
YoY Change
Other Investing Activities $1.034B -$1.065B -$3.789B
YoY Change -132.03% -72.32% 2513.1%
Cash From Investing Activities $945.0M -$1.152B -$3.921B
YoY Change -128.4% -70.29% 2078.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $623.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.041B -1.327B -$642.0M
YoY Change 51950.0% 5429.17% -2569.23%
NET CHANGE
Cash From Operating Activities 252.0M 304.0M $2.763B
Cash From Investing Activities 945.0M -1.152B -$3.921B
Cash From Financing Activities -1.041B -1.327B -$642.0M
Net Change In Cash 156.0M -2.175B -$1.800B
YoY Change -394.34% -1450.93% -163.9%
FREE CASH FLOW
Cash From Operating Activities $252.0M $304.0M $2.763B
Capital Expenditures -$89.00M -$87.00M $132.0M
Free Cash Flow $341.0M $391.0M $2.631B
YoY Change -89.9% -90.45% -10.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38753
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Maximum Remaining Maturity Of Foreign Currency Derivatives1
MaximumRemainingMaturityOfForeignCurrencyDerivatives1
P15M
dei Entity Central Index Key
EntityCentralIndexKey
0001682852
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q2 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Entity Registrant Name
EntityRegistrantName
Moderna, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3467528
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Technology Square
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge,
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
714-6500
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
MRNA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
391199544 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2873000000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6848000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5024000000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
3879000000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2691000000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3175000000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
1921000000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
1441000000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1054000000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
728000000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
13563000000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
16071000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
10162000000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
6843000000 usd
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1324000000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1241000000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
122000000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142000000 usd
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12000000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12000000 usd
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
785000000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
326000000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
75000000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
34000000 usd
CY2022Q2 us-gaap Assets
Assets
26043000000 usd
CY2021Q4 us-gaap Assets
Assets
24669000000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
181000000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
302000000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1780000000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1472000000 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4093000000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6253000000 usd
CY2022Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
349000000 usd
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
876000000 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
409000000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
225000000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6812000000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9128000000 usd
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
405000000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
615000000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
87000000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106000000 usd
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
641000000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
599000000 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
113000000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
76000000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
8058000000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
10524000000 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
392000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
392000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
403000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
403000000 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2413000000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4211000000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-240000000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-24000000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
15812000000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
9958000000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
17985000000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14145000000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26043000000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24669000000 usd
CY2022Q2 us-gaap Revenues
Revenues
4749000000 usd
CY2021Q2 us-gaap Revenues
Revenues
4354000000 usd
us-gaap Revenues
Revenues
10815000000 usd
us-gaap Revenues
Revenues
6291000000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1381000000 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
750000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2398000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
943000000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
710000000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
421000000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1264000000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
822000000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
211000000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
121000000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
479000000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
198000000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
2302000000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
1292000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
4141000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1963000000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
2447000000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3062000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
6674000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
4328000000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
40000000 usd
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
55000000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
7000000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2474000000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3063000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6703000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4323000000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
277000000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
283000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
849000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
322000000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
2197000000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
2780000000 usd
us-gaap Net Income Loss
NetIncomeLoss
5854000000 usd
us-gaap Net Income Loss
NetIncomeLoss
4001000000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.55
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
14.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.98
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.24
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
13.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.30
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
396000000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
402000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
399000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
401000000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
419000000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
431000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
423000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
430000000 shares
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
2197000000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
2780000000 usd
us-gaap Net Income Loss
NetIncomeLoss
5854000000 usd
us-gaap Net Income Loss
NetIncomeLoss
4001000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-80000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-258000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-8000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
1000000 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-15000000 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
1000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-72000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-6000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-243000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-8000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
46000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
21000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
71000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
21000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
30000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
0 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
44000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
0 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
16000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
21000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
27000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
21000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-56000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-216000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
13000000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2141000000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2795000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5638000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4014000000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
17075000000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
9000000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
9000000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-56000000 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1298000000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
2197000000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
17985000000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
3838000000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31000000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15000000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
2780000000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
6704000000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14145000000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
9000000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
9000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
94000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-216000000 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1921000000 usd
us-gaap Net Income Loss
NetIncomeLoss
5854000000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
17985000000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2561000000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
59000000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
65000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
13000000 usd
us-gaap Net Income Loss
NetIncomeLoss
4001000000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
6704000000 usd
us-gaap Net Income Loss
NetIncomeLoss
5854000000 usd
us-gaap Net Income Loss
NetIncomeLoss
4001000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
94000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
65000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
155000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
84000000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-29000000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-13000000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-376000000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-72000000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-15000000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-484000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
629000000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
324000000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
110000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
480000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
596000000 usd
mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
-20000000 usd
mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
14000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-56000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
44000000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
305000000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
367000000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2370000000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3433000000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-527000000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
377000000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-19000000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
8000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
263000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
63000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3067000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7034000000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
8734000000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
6559000000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
1409000000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
860000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2506000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1706000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
219000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
65000000 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
35000000 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5073000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4058000000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
29000000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
64000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1921000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
77000000 usd
CY2022Q2 mrna Operating Lease Number Of Properties
OperatingLeaseNumberOfProperties
2 campus
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1969000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2000000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
62000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3975000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2978000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6860000000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2636000000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2885000000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5614000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
49000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
45000000 usd
mrna Right Of Use Assets Obtained Through Finance Lease Modifications And Reassessments
RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments
0 usd
mrna Right Of Use Assets Obtained Through Finance Lease Modifications And Reassessments
RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments
363000000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
94000000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
126000000 usd
us-gaap Use Of Estimates
UseOfEstimates
We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, income taxes, valuation allowance on deferred tax assets, leases, fair value of financial instruments, derivative financial instruments, inventory, firm purchase commitment liabilities, useful lives of property and equipment, research and development expenses, and stock-based compensation. The actual results that we experience may differ materially from our estimates.
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-160000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-56000000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2873000000 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5603000000 usd
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12000000 usd
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11000000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2885000000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5614000000 usd
CY2021Q4 mrna Number Of Participants
NumberOfParticipants
30000 participant
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
5079000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
5024000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
10485000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
10162000000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15564000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
15186000000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
3882000000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
3879000000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
6892000000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6843000000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10774000000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
10722000000 usd
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 usd
CY2021Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 usd
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
357000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
13640000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
21000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
517000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
378000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
14157000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
52000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
9346000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
52000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
9347000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
634 security
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
384 security
CY2022Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
30000000 usd
CY2021Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
0 usd
CY2022Q2 us-gaap Foreign Currency Cash Flow Hedge Gain Loss To Be Reclassified During Next12 Months
ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
55000000 usd
CY2022Q2 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
2110000000 usd
CY2022Q2 us-gaap Derivative Assets
DerivativeAssets
58000000 usd
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
2000000 usd
CY2021Q4 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1935000000 usd
CY2021Q4 us-gaap Derivative Assets
DerivativeAssets
21000000 usd
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
7000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
46000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
21000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
71000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
21000000 usd
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1400000000 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
870000000 usd
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
379000000 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
338000000 usd
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
142000000 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
233000000 usd
CY2021Q2 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
148000000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
1921000000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
1441000000 usd
CY2022Q2 us-gaap Inventory Write Down
InventoryWriteDown
499000000 usd
us-gaap Inventory Write Down
InventoryWriteDown
689000000 usd
CY2021Q2 us-gaap Inventory Write Down
InventoryWriteDown
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
0 usd
CY2022Q2 us-gaap Inventory Firm Purchase Commitment Loss
InventoryFirmPurchaseCommitmentLoss
184000000 usd
us-gaap Inventory Firm Purchase Commitment Loss
InventoryFirmPurchaseCommitmentLoss
342000000 usd
CY2022Q2 mrna Legal Contingency Future Firm Purchase Commitments
LegalContingencyFutureFirmPurchaseCommitments
342000000 usd
CY2021Q2 us-gaap Inventory Firm Purchase Commitment Loss
InventoryFirmPurchaseCommitmentLoss
0 usd
CY2021Q4 mrna Legal Contingency Future Firm Purchase Commitments
LegalContingencyFutureFirmPurchaseCommitments
0 usd
us-gaap Inventory Firm Purchase Commitment Loss
InventoryFirmPurchaseCommitmentLoss
0 usd
CY2022Q2 us-gaap Other Inventory Capitalized Costs
OtherInventoryCapitalizedCosts
155000000 usd
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
1790000000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
1593000000 usd
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
466000000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
352000000 usd
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1324000000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1241000000 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
76000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
155000000 usd
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
69000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
84000000 usd
CY2022Q2 mrna Other Prepaid Expense Materials And Supplies
OtherPrepaidExpenseMaterialsAndSupplies
474000000 usd
CY2021Q4 mrna Other Prepaid Expense Materials And Supplies
OtherPrepaidExpenseMaterialsAndSupplies
287000000 usd
CY2022Q2 mrna Other Prepaid Expense Manufacturing
OtherPrepaidExpenseManufacturing
183000000 usd
CY2021Q4 mrna Other Prepaid Expense Manufacturing
OtherPrepaidExpenseManufacturing
118000000 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
110000000 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
126000000 usd
CY2022Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
45000000 usd
CY2021Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
70000000 usd
CY2022Q2 mrna Tenant Improvement Allowance Receivable Current
TenantImprovementAllowanceReceivableCurrent
51000000 usd
CY2021Q4 mrna Tenant Improvement Allowance Receivable Current
TenantImprovementAllowanceReceivableCurrent
51000000 usd
CY2022Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
57000000 usd
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
27000000 usd
CY2022Q2 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
58000000 usd
CY2021Q4 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
21000000 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
76000000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
28000000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1054000000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
728000000 usd
CY2022Q2 mrna Accrued Clinical Trials
AccruedClinicalTrials
324000000 usd
CY2021Q4 mrna Accrued Clinical Trials
AccruedClinicalTrials
283000000 usd
CY2022Q2 mrna Raw Materials Accounts Payable
RawMaterialsAccountsPayable
317000000 usd
CY2021Q4 mrna Raw Materials Accounts Payable
RawMaterialsAccountsPayable
260000000 usd
CY2022Q2 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
158000000 usd
CY2021Q4 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
241000000 usd
CY2022Q2 mrna Accrued Development Operation
AccruedDevelopmentOperation
65000000 usd
CY2021Q4 mrna Accrued Development Operation
AccruedDevelopmentOperation
137000000 usd
CY2022Q2 mrna Accrued Manufacturing
AccruedManufacturing
244000000 usd
CY2021Q4 mrna Accrued Manufacturing
AccruedManufacturing
227000000 usd
CY2022Q2 mrna Accrued Other External Goods And Services Current
AccruedOtherExternalGoodsAndServicesCurrent
100000000 usd
CY2021Q4 mrna Accrued Other External Goods And Services Current
AccruedOtherExternalGoodsAndServicesCurrent
79000000 usd
CY2022Q2 mrna Legal Contingency Future Firm Purchase Commitments
LegalContingencyFutureFirmPurchaseCommitments
342000000 usd
CY2021Q4 mrna Legal Contingency Future Firm Purchase Commitments
LegalContingencyFutureFirmPurchaseCommitments
0 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
128000000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
126000000 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
102000000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
119000000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1780000000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1472000000 usd
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
121000000 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
165000000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38000000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
46000000 usd
CY2022Q2 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
250000000 usd
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
14000000 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
409000000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
225000000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6868000000 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
1840000000 usd
mrna Contract With Customer Liability Deductions During Period
ContractWithCustomerLiabilityDeductionsDuringPeriod
4210000000 usd
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4498000000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
122000000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142000000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
232000000 usd
CY2022Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
619000000 usd
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
665000000 usd
CY2022Q2 mrna Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
741000000 usd
CY2021Q4 mrna Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
807000000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38000000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
46000000 usd
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
121000000 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
165000000 usd
CY2022Q2 mrna Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
159000000 usd
CY2021Q4 mrna Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
211000000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
87000000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106000000 usd
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
641000000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
599000000 usd
CY2022Q2 mrna Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
728000000 usd
CY2021Q4 mrna Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
705000000 usd
CY2022Q2 mrna Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
887000000 usd
CY2021Q4 mrna Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
916000000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
23000000 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
121000000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
39000000 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
38000000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
15000000 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
21000000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16000000 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
22000000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16000000 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
22000000 usd
CY2022Q2 mrna Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
51000000 usd
CY2022Q2 mrna Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
1111000000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
160000000 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1335000000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
35000000 usd
CY2022Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
573000000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
125000000 usd
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
762000000 usd
CY2022Q2 mrna Legal Contingency Future Firm Purchase Commitments
LegalContingencyFutureFirmPurchaseCommitments
342000000 usd
CY2022Q2 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
157000000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
364000000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50000000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
94000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
65000000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50000000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
94000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
65000000 usd
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
575000000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2474000000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3063000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6703000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4323000000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
277000000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
283000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
849000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
322000000 usd
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.112
CY2021Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.092
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.127
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.075
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
2197000000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
2780000000 usd
us-gaap Net Income Loss
NetIncomeLoss
5854000000 usd
us-gaap Net Income Loss
NetIncomeLoss
4001000000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
396000000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
402000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
399000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
401000000 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
23000000 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
23000000 shares
CY2021Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
29000000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
24000000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
29000000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
419000000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
431000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
423000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
430000000 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.55
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
14.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.98
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.24
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
13.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.30
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4000000 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000000 shares

Files In Submission

Name View Source Status
0001682852-22-000042-index-headers.html Edgar Link pending
0001682852-22-000042-index.html Edgar Link pending
0001682852-22-000042.txt Edgar Link pending
0001682852-22-000042-xbrl.zip Edgar Link pending
exhibit101-arnonxemployeed.htm Edgar Link pending
exhibit104-bardaamendmentn.htm Edgar Link pending
exhibit106-dodno24.htm Edgar Link pending
exhibit3116302022.htm Edgar Link pending
exhibit3126302022.htm Edgar Link pending
exhibit3216302022.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrna-20220630.htm Edgar Link pending
mrna-20220630.xsd Edgar Link pending
mrna-20220630_cal.xml Edgar Link unprocessable
mrna-20220630_def.xml Edgar Link unprocessable
mrna-20220630_g1.jpg Edgar Link pending
mrna-20220630_g2.jpg Edgar Link pending
mrna-20220630_htm.xml Edgar Link completed
mrna-20220630_lab.xml Edgar Link unprocessable
mrna-20220630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending